AVTX Annual CFI
-$133.00 K
-$38.00 K-40.00%
31 December 2023
Summary:
As of January 23, 2025, AVTX annual cash flow from investing activities is -$133.00 thousand, with the most recent change of -$38.00 thousand (-40.00%) on December 31, 2023. During the last 3 years, it has fallen by -$11.27 million (-101.19%). AVTX annual CFI is now -101.19% below its all-time high of $11.13 million, reached on December 31, 2020.AVTX Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AVTX Quarterly CFI
$0.00
$0.000.00%
30 September 2024
Summary:
As of January 23, 2025, AVTX quarterly cash flow from investing activities is $0.00, unchanged on September 30, 2024. Over the past year, it has stayed the same.AVTX quarterly CFI is now -100.00% below its all-time high of $12.84 million, reached on June 30, 2020.AVTX Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AVTX TTM CFI
$356.00 K
$0.000.00%
30 September 2024
Summary:
As of January 23, 2025, AVTX TTM cash flow from investing activities is $356.00 thousand, unchanged on September 30, 2024. Over the past year, it has stayed the same.AVTX TTM CFI is now -97.12% below its all-time high of $12.36 million, reached on March 31, 2021.AVTX TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AVTX Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -40.0% | 0.0% | 0.0% |
| 3 y3 years | -101.2% | 0.0% | +474.7% |
| 5 y5 years | -115.4% | +100.0% | +474.7% |
AVTX Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -40.0% | at low | -100.0% | +100.0% | at high | +256.1% |
| 5 y | 5-year | -101.2% | +70.0% | -100.0% | +100.0% | -97.1% | +123.3% |
| alltime | all time | -101.2% | +99.3% | -100.0% | +100.0% | -97.1% | +101.9% |
Avalo Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $0.00(0.0%) | $356.00 K(0.0%) |
| June 2024 | - | $0.00(-100.0%) | $356.00 K(0.0%) |
| Mar 2024 | - | $356.00 K(>+9900.0%) | $356.00 K(-367.7%) |
| Dec 2023 | -$133.00 K(+40.0%) | $0.00(0.0%) | -$133.00 K(0.0%) |
| Sept 2023 | - | $0.00(0.0%) | -$133.00 K(-22.7%) |
| June 2023 | - | $0.00(-100.0%) | -$172.00 K(-24.6%) |
| Mar 2023 | - | -$133.00 K(<-9900.0%) | -$228.00 K(+140.0%) |
| Dec 2022 | -$95.00 K(-15.9%) | $0.00(-100.0%) | -$95.00 K(-10.4%) |
| Sept 2022 | - | -$39.00 K(-30.4%) | -$106.00 K(-28.4%) |
| June 2022 | - | -$56.00 K(<-9900.0%) | -$148.00 K(+60.9%) |
| Mar 2022 | - | $0.00(-100.0%) | -$92.00 K(-18.6%) |
| Dec 2021 | -$113.00 K(-101.0%) | -$11.00 K(-86.4%) | -$113.00 K(-77.1%) |
| Sept 2021 | - | -$81.00 K(<-9900.0%) | -$493.00 K(+3.8%) |
| June 2021 | - | $0.00(-100.0%) | -$475.00 K(-103.8%) |
| Mar 2021 | - | -$21.00 K(-94.6%) | $12.36 M(+11.0%) |
| Dec 2020 | $11.13 M(-2612.9%) | -$391.00 K(+520.6%) | $11.13 M(-1.9%) |
| Sept 2020 | - | -$63.00 K(-100.5%) | $11.34 M(-0.5%) |
| June 2020 | - | $12.84 M(-1126.1%) | $11.40 M(-846.0%) |
| Mar 2020 | - | -$1.25 M(+591.2%) | -$1.53 M(+244.9%) |
| Dec 2019 | -$443.00 K | -$181.00 K(+3449.0%) | -$443.10 K(-41.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2019 | - | -$5100.00(-94.4%) | -$761.50 K(-220.1%) |
| June 2019 | - | -$91.00 K(-45.2%) | $634.30 K(-11.7%) |
| Mar 2019 | - | -$166.00 K(-66.8%) | $718.60 K(-17.0%) |
| Dec 2018 | $865.50 K(-104.6%) | -$499.40 K(-135.9%) | $865.40 K(-104.9%) |
| Sept 2018 | - | $1.39 M(<-9900.0%) | -$17.54 M(-7.4%) |
| June 2018 | - | -$6700.00(-65.1%) | -$18.94 M(+0.0%) |
| Mar 2018 | - | -$19.20 K(-99.9%) | -$18.93 M(+0.1%) |
| Dec 2017 | -$18.91 M(>+9900.0%) | -$18.90 M(>+9900.0%) | -$18.91 M(>+9900.0%) |
| Sept 2017 | - | -$6200.00(<-9900.0%) | -$17.20 K(-1.7%) |
| June 2017 | - | $0.00(-100.0%) | -$17.50 K(-37.1%) |
| Mar 2017 | - | -$1800.00(-80.4%) | -$27.80 K(-20.3%) |
| Dec 2016 | -$34.90 K(+74.5%) | -$9200.00(+41.5%) | -$34.90 K(+35.8%) |
| Sept 2016 | - | -$6500.00(-36.9%) | -$25.70 K(-34.4%) |
| June 2016 | - | -$10.30 K(+15.7%) | -$39.20 K(+35.6%) |
| Mar 2016 | - | -$8900.00(<-9900.0%) | -$28.90 K(+44.5%) |
| Dec 2015 | -$20.00 K(+2.6%) | $0.00(-100.0%) | -$20.00 K(0.0%) |
| Sept 2015 | - | -$20.00 K(<-9900.0%) | -$20.00 K(+2.6%) |
| Dec 2014 | -$19.50 K(-33.4%) | $0.00(-100.0%) | -$19.50 K(0.0%) |
| Sept 2014 | - | -$19.50 K | -$19.50 K |
| Dec 2013 | -$29.30 K | - | - |
FAQ
- What is Avalo Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Avalo Therapeutics?
- What is Avalo Therapeutics annual CFI year-on-year change?
- What is Avalo Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Avalo Therapeutics?
- What is Avalo Therapeutics quarterly CFI year-on-year change?
- What is Avalo Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Avalo Therapeutics?
- What is Avalo Therapeutics TTM CFI year-on-year change?
What is Avalo Therapeutics annual cash flow from investing activities?
The current annual CFI of AVTX is -$133.00 K
What is the all time high annual CFI for Avalo Therapeutics?
Avalo Therapeutics all-time high annual cash flow from investing activities is $11.13 M
What is Avalo Therapeutics annual CFI year-on-year change?
Over the past year, AVTX annual cash flow from investing activities has changed by -$38.00 K (-40.00%)
What is Avalo Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of AVTX is $0.00
What is the all time high quarterly CFI for Avalo Therapeutics?
Avalo Therapeutics all-time high quarterly cash flow from investing activities is $12.84 M
What is Avalo Therapeutics quarterly CFI year-on-year change?
Over the past year, AVTX quarterly cash flow from investing activities has changed by $0.00 (0.00%)
What is Avalo Therapeutics TTM cash flow from investing activities?
The current TTM CFI of AVTX is $356.00 K
What is the all time high TTM CFI for Avalo Therapeutics?
Avalo Therapeutics all-time high TTM cash flow from investing activities is $12.36 M
What is Avalo Therapeutics TTM CFI year-on-year change?
Over the past year, AVTX TTM cash flow from investing activities has changed by $0.00 (0.00%)